Jan Marsal
11 – 20 of 46
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
Mycophenolate mofetil for systemic sclerosis : Drug exposure exhibits considerable inter-individual variation-a prospective, observational study
(
- Contribution to journal › Article
-
Mark
Irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls : Is it an overlooked comorbidity?
(
- Contribution to journal › Letter
-
Mark
Short and long-term efficacy of adalimumab in ulcerative colitis : a real-life study
(
- Contribution to journal › Article
- 2019
-
Mark
Exocrine pancreatic function is preserved in systemic sclerosis
(
- Contribution to journal › Article
-
Mark
Elevated faecal calprotectin is linked to worse disease status in axial spondyloarthritis : Results from the SPARTAKUS cohort
(
- Contribution to journal › Article
- 2018
-
Mark
Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease
(
- Contribution to journal › Article
-
Mark
Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease
(
- Contribution to journal › Article
- 2017
-
Mark
Letter: how to define remission in ulcerative colitis – histological remission should be considered. Authors' reply
(
- Contribution to journal › Letter
-
Mark
Long-term effectiveness of vedolizumab in inflammatory bowel disease : a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)
(
- Contribution to journal › Article
-
Mark
Long-term outcome of infliximab treatment in chronic active ulcerative colitis : a Swedish multicentre study of 250 patients
(
- Contribution to journal › Article